Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057863 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
A Phase 2 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00057863 is a Phase 2 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 120-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00057863, a Phase 2 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of combining oxaliplatin with paclitaxel in treating patients who have locally recurrent or metastatic cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Paclitaxel
Study Locations (1)
New York
- Montefiore Medical Center - Moses Campus - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2003-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057863
The ClinicalTrials.gov registry entry for NCT00057863 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cervical Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT00057863 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00057863 about?
NCT00057863 is a clinical study titled "Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer". Phase II trial to study the effectiveness of combining oxaliplatin with paclitaxel in treating patients who have locally recurrent or metastatic cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug ...
What is the current status of trial NCT00057863?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2003-01. Estimated completion is 2010-03.
What conditions does trial NCT00057863 study?
This clinical trial studies the following conditions: Cervical Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer.
What interventions are being tested in trial NCT00057863?
The interventions under investigation include: Oxaliplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00057863?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00057863 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
COMPLETED · Phase 2
-
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
COMPLETED · Phase 2
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.